Home/Pipeline/CT-P53

CT-P53

Multiple sclerosis

Phase 3Active

Key Facts

Indication

Multiple sclerosis

Phase

Phase 3

Status

Active

Company

Celltrion

About Celltrion

Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.

View full company profile

Therapeutic Areas

Immunology Oncology Autoimmune Diseases Ophthalmology Respiratory

Other Multiple sclerosis Drugs

Drug	Company	Phase	Status
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Evobrutinib	Merck KGaA	Phase 3	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
REBIF (interferon beta-1a)	EMD Serono	Approved	Active (Lifecycle Management)